Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.71 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.71 |
| ▸ | USP7 | Q93009 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | STAT3 | P40763 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.61 |
| ▸ | NOS2 | P35228 | 8/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22875562 | 1.00 | MBOAT4 (0.71) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL19785025 | 1.00 | MBOAT4 (0.71) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL20853384 | 1.00 | MBOAT4 (0.71) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL20750769 | 1.00 | MBOAT4 (0.71) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022884 | 0.93 | MBOAT4 (0.61) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022539 | 0.93 | RORC (0.72) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022889 | 0.93 | RORC (0.72) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022617 | 0.93 | MBOAT4 (0.61) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL21022890 | 0.92 | MBOAT4 (0.60) | MBOAT4NFE2L2USP7USP2STAT3 | |
| SCHEMBL19708265 | 0.91 | MBOAT4 (0.60) | MBOAT4NFE2L2USP7USP2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | Reata Pharmaceuticals Holdings, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | Reata Pharmaceuticals Holdings, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | REATA PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | REATA PHARMACEUTICALS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20190076443-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-10208082-B2 | Sustained-release pharmaceutical composition for treatment and prevention of eye disease | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-19 | — | — | US | disclosed |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | REATA PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170260228-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF EYE DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-09-14 | — | — | US | disclosed |
| US-9670147-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | REATA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911395-B2 | Methods of treating obesity using antioxidant inflammation modulators | TXNRD2, HMOX1, GPX4 | MBOAT4 92/4885NFE2L2 12/4885USP7 1458/4885 |
| US-20200289607-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CORNEAL ENDOTHELIUM DISORDERS | FECH, KEAP1, NFE2L2 | MBOAT4 4178/4885NFE2L2 3/4885USP7 3485/4885 |
| US-20180161311-A1 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE | LIPG, CYP27A1, CYP11B1 | MBOAT4 1458/4885NFE2L2 315/4885USP7 4046/4885 |
| US-11919838-B2 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 415/4885NFE2L2 9/4885USP7 484/4885 |
| US-20220024862-A1 | ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 | IL17A, ALOX15, ALOX12 | MBOAT4 415/4885NFE2L2 9/4885USP7 484/4885 |
| US-20190076443-A1 | METHODS OF TREATING OBESITY USING ANTIOXIDANT INFLAMMATION MODULATORS | TXNRD2, HMOX1, GPX4 | MBOAT4 92/4885NFE2L2 12/4885USP7 1458/4885 |
| US-20210161914-A1 | METHODS OF TREATING ALPORT SYNDROME USING BARDOXOLONE METHYL OR ANALOGS THEREOF | HSD11B2, CYP21A2, HSD11B1 | MBOAT4 912/4885NFE2L2 766/4885USP7 3465/4885 |
| US-20170260228-A1 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF EYE DISEASE | KEAP1, NFE2L2, RELA | MBOAT4 3660/4885NFE2L2 2/4885USP7 2310/4885 |
| US-10208082-B2 | Sustained-release pharmaceutical composition for treatment and prevention of eye disease | KEAP1, NFE2L2, RELA | MBOAT4 3660/4885NFE2L2 2/4885USP7 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.